Wally R Smith

List of Publications by Year in Descending Order

63 papers	3,644 citations	25 h-index	60 g-index
66 ext. papers	4,490 ext. citations	6.7 avg, IF	4.84 L-index

#	Paper	IF	Citations
63	Moving Toward a Multimodal Analgesic Regimen for Acute Sickle Cell Pain with Non-Opioid Analgesic Adjuncts: A Narrative Review.. *Journal of Pain Research*, **2022**, 15, 879-894	2.9	0
62	Gender-specific correlates of nonmedical use of prescription medications in a diverse primary care sample.. *Drug and Alcohol Dependence*, **2022**, 234, 109399	4.9	
61	Telehealth acceptability and opioid prescribing patterns of providers of painful chronic diseases during the COVID-19 pandemic: A survey of sickle cell providers.. *Journal of Opioid Management*, **2021**, 17, 489-497	0.8	
60	A randomised controlled provider-blinded trial of community health workers in sickle cell anaemia: effects on haematologic variables and hydroxyurea adherence. *British Journal of Haematology*, **2021**,	4.5	2
59	Indirect Economic Burden of Sickle Cell Disease. *Value in Health*, **2021**, 24, 1095-1101	3.3	2
58	Development of a Severity Classification System for Sickle Cell Disease. *ClinicoEconomics and Outcomes Research*, **2020**, 12, 625-633	1.7	5
57	Hyperuricemia is associated with a lower glomerular filtration rate in pediatric sickle cell disease patients. *Pediatric Nephrology*, **2020**, 35, 883-889	3.2	5
56	Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects. *Blood Advances*, **2020**, 4, 3804-3813	7.8	12
55	Health-related quality of life in sickle cell disease. *Nature Reviews Disease Primers*, **2019**, 5, 27	51.1	0
54	Lessons Learned from Building a Pediatric-to-Adult Sickle Cell Transition Program. *Southern Medical Journal*, **2019**, 112, 190-197	0.6	11
53	Crizanlizumab Versus Placebo, with or without Hydroxyurea/Hydroxycarbamide, in Adolescent and Adult Patients with Sickle Cell Disease and Vaso-Occlusive Crises: A Randomized, Double-Blind, Phase III Study (STAND). *Blood*, **2019**, 134, 998-998	2.2	1
52	Development and Validation of a Functional Status-Based Pain Assessment Tool. *Blood*, **2019**, 134, 416-416	2.2	
51	Responsivity of Utilization Rates to the Intensity of Case Management over Time Among High-Utilizing Adults with Sickle Cell Disease. *Blood*, **2019**, 134, 5803-5803	2.2	
50	Case Management Featuring Community Health Workers Reduces Inpatient Health Care Utilization in Adults with Sickle Cell Disease. *Blood*, **2019**, 134, 2104-2104	2.2	
49	Using Lean Six Sigma to Develop a Patient Centered Medical Home for Adults with Sickle Cell Disease. *Blood*, **2019**, 134, 3408-3408	2.2	
48	Severity Classification for Sickle Cell Disease: A RAND/UCLA Modified Delphi Panel. *Blood*, **2019**, 134, 415-415	2.2	0
47	The Effect of Patient Navigators on Health-Related Quality of Life in Sickle Cell Anemia: The SHIP-HU Study. *Blood*, **2019**, 134, 2168-2168	2.2	1

46	Tiered Oral Therapy Protocol for Sickle Cell Vaso-Occlusive Crisis. *Blood*, **2019**, 134, 3446-3446	2.2	
45	The Effect of Patient Navigators on Laboratory Parameters of Hydroxyurea Adherence in Sickle Cell Anemia: The SHIP-HU Study. *Blood*, **2019**, 134, 2309-2309	2.2	1
44	Development of a Framework to Describe Functions and Practice of Community Health Workers. *Journal of Continuing Education in the Health Professions*, **2019**, 39, 274-278	2.1	2
43	AAAPT Diagnostic Criteria for Acute Sickle Cell Disease Pain. *Journal of Pain*, **2019**, 20, 746-759	5.2	20
42	Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study. *American Journal of Hematology*, **2019**, 94, 446-454	7.1	28
41	Prescription Opioid Misuse Index in sickle cell patients: A brief questionnaire to assess at-risk for opioid abuse. *Journal of Opioid Management*, **2019**, 15, 323-331	0.8	1
40	Predictive Ability of Intermittent Daily Sickle Cell Pain Assessment: The PiSCES Project. *Pain Medicine*, **2018**, 19, 1972-1981	2.8	0
39	Sickle cell disease. *Nature Reviews Disease Primers*, **2018**, 4, 18010	51.1	373
38	A Phase 3 Trial of l-Glutamine in Sickle Cell Disease. *New England Journal of Medicine*, **2018**, 379, 226-235	59.2	212
37	AAPT Diagnostic Criteria for Chronic Sickle Cell Disease Pain. *Journal of Pain*, **2017**, 18, 490-498	5.2	93
36	Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. *New England Journal of Medicine*, **2017**, 376, 429-439	59.2	381
35	Comorbidity, Pain, Utilization, and Psychosocial Outcomes in Older versus Younger Sickle Cell Adults: The PiSCES Project. *BioMed Research International*, **2017**, 2017, 4070547	3	30
34	Survey of Physician Perspective towards Management of Pain for Chronic Conditions in the Emergency Department **2017**, 1, 55-70		0
33	Community Health Workers as Support for Sickle Cell Care. *American Journal of Preventive Medicine*, **2016**, 51, S87-98	6.1	37
32	Quality of care in sickle cell disease: Cross-sectional study and development of a measure for adults reporting on ambulatory and emergency department care. *Medicine (United States)*, **2016**, 95, e4528	1.8	25
31	Top 10 Things You Need to Know to Run Community Health Worker Programs: Lessons Learned in the Field. *Southern Medical Journal*, **2016**, 109, 579-82	0.6	4
30	Self-efficacy and readiness for transition from pediatric to adult care in sickle cell disease. *International Journal of Adolescent Medicine and Health*, **2016**, 28, 381-388	1.1	21
29	Health literacy and disease-specific knowledge of caregivers for children with sickle cell disease. *Pediatric Hematology and Oncology*, **2016**, 33, 121-33	1.7	13

28	PhysiciansTPerception of Sickle-cell Disease Pain. *Journal of the National Medical Association*, **2016**, 108, 113-8	2.3	3
27	Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use. *Blood*, **2015**, 125, 2656-64	2.2	154
26	Daily home opioid use in adults with sickle cell disease: The PiSCES project. *Journal of Opioid Management*, **2015**, 11, 243-53	0.8	35
25	Fatigue in adolescents and young adults with sickle cell disease: biological and behavioral correlates and health-related quality of life. *Journal of Pediatric Oncology Nursing*, **2014**, 31, 6-17	2	49
24	Use of the Word "Crisis" in Sickle Cell Disease: The Language of Sickle Cell. *Journal of the National Medical Association*, **2014**, 106, 23-30	2.3	1
23	Disparities in breast and cervical cancer screening in women with mental illness: a systematic literature review. *American Journal of Preventive Medicine*, **2013**, 44, 392-398	6.1	62
22	Effects Of GMI 1070, a Pan-Selectin Inhibitor, On Pain Intensity and Opioid Utilization In Sickle Cell Disease. *Blood*, **2013**, 122, 775-775	2.2	2
21	GMI 1070: Reduction In Time To Resolution Of Vaso-Occlusive Crisis and Decreased Opioid Use In a Prospective, Randomized, Multi-Center Double Blind, Adaptive Phase 2 Study In Sickle Cell Disease. *Blood*, **2013**, 122, 776-776	2.2	6
20	Disease-Specific Knowledge Assessment of Caregivers Is a Better Predictor of Health Care Utilization Than Caregiver Functional Health Literacy Among Children with Sickle Cell Disease. *Blood*, **2012**, 120, 4240-4240	2.2	1
19	Somatic symptom burden in adults with sickle cell disease predicts pain, depression, anxiety, health care utilization, and quality of life: the PiSCES project. *Psychosomatics*, **2011**, 52, 272-9	2.6	56
18	Emerging biobehavioral factors of fatigue in sickle cell disease. *Journal of Nursing Scholarship*, **2011**, 43, 22-9	3.6	28
17	Frequently asked questions by hospitalists managing pain in adults with sickle cell disease. *Journal of Hospital Medicine*, **2011**, 6, 297-303	2.7	21
16	Sickle-cell pain: advances in epidemiology and etiology. *Hematology American Society of Hematology Education Program*, **2010**, 2010, 409-15	3.1	64
15	The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. *American Journal of Hematology*, **2010**, 85, 403-8	7.1	290
14	Readiness for Transition From Pediatric Sickle Cell Care: Exploratory Analyses of Domains of Readiness and Total Scores. *Blood*, **2010**, 116, 2576-2576	2.2	1
13	Pain site frequency and location in sickle cell disease: the PiSCES project. *Pain*, **2009**, 145, 246-51	8	62
12	Climatic and geographic temporal patterns of pain in the Multicenter Study of Hydroxyurea. *Pain*, **2009**, 146, 91-8	8	37
11	Daily assessment of pain in adults with sickle cell disease. *Annals of Internal Medicine*, **2008**, 148, 94-101	8	366

10	Depression and anxiety in adults with sickle cell disease: the PiSCES project. *Psychosomatic Medicine* , **2008**, 70, 192-6	3.7	133
9	Alcohol abuse in sickle cell disease: the Pisces Project. *American Journal on Addictions*, **2007**, 16, 383-8	3.7	19
8	The role of catastrophizing in sickle cell disease--the PiSCES project. *Pain*, **2007**, 133, 39-46	8	39
7	Health related quality of life in sickle cell patients: the PiSCES project. *Health and Quality of Life Outcomes*, **2005**, 3, 50	3	163
6	Understanding pain and improving management of sickle cell disease: the PiSCES study. *Journal of the National Medical Association*, **2005**, 97, 183-93	2.3	65
5	Efficacy and Safety of the Gardos Channel Inhibitor, ICA-17043, in Patients with Sickle Cell Anemia.. *Blood*, **2004**, 104, 103-103	2.2	2
4	Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. *JAMA - Journal of the American Medical Association*, **2003**, 289, 1645-51	27.4	592
3	Prognostic judgments and triage decisions for patients with acute congestive heart failure. *Chest*, **2002**, 121, 1610-7	5.3	61
2	Results of report cards for patients with congestive heart failure depend on the method used to adjust for severity. *Annals of Internal Medicine*, **2000**, 133, 10-20	8	22
1	Psychosocial determinants of health care utilization in sickle cell disease patients. *Annals of Behavioral Medicine*, **1997**, 19, 171-8	4.5	30